15 assets in Thyroid Gland Undifferentiated (Anaplastic) Carcinoma

Therapeutic assets addressing Thyroid Gland Undifferentiated (Anaplastic) Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Trametinib Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	Cancer Research UK	P2/3	B (61)
Cobimetinib Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	Cancer Research UK	P2/3	B (56)
Dabrafenib Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	Cancer Research UK	P2/3	B (56)
Vemurafenib Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	Cancer Research UK	P2/3	CCC (55)
Cyclophosphamide Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Domvanalimab Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	Hospices Civils de Lyon	P2	CCC (53)
Fludarabine Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Ipilimumab Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Lifileucel Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Nivolumab Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Zimberelimab Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	Hospices Civils de Lyon	P2	CCC (53)
Cetuximab Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	C4 Therapeutics, Inc.	P1	CC (47)
cft1946 Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	C4 Therapeutics, Inc.	P1	CC (47)
cd70-targeting car-t cells Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	Chongqing Precision Biotech Co., Ltd	P1	CC (43)
[177lu]lu-akir001 Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	Karolinska University Hospital	Early P1	C (39)